ABIO Stock: ARCA biopharma, Inc. Stock Price, Analysis & Insights
Get live abio stock price $28.80, comprehensive ARCA biopharma, Inc. stock analysis, charts, news, and expert forecast. Real-time abio stock data and investment insights.
Loading chart...
Company Overview
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Company Information
- CEO
- Thomas A. Keuer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
Contact Information
- Website
- https://www.arcabio.com
- Address
- 10170 Church Ranch Way
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
ARCA biopharma, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Thomas A. Keuer, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
ARCA biopharma, Inc. competes in the Biotechnology within the broader Healthcare. With 34.8 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, ARCA biopharma, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating ARCA biopharma, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for ARCA biopharma, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for ARCA biopharma, Inc.
- ⚠Investors should consider how ARCA biopharma, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
34.82M
P/E Ratio
-4.90
Beta
0.90
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 34.82M market capitalization
- Trading Volume: 290.85K shares traded today
- Price Range: 52-week range of $2.25 - $53.88
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for ARCA biopharma, Inc.
ARCA biopharma, Inc. (ABIO) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 34.82M, the company represents a significant player in its market. The stock is currently trading at $28.80 with a positivedaily change of 1052.00%.
The company's 3 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -4.90, beta of 0.90, and 52-week price range from $2.25 to $53.88when evaluating investment opportunities.
Why Invest in ARCA biopharma, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Thomas A. Keuer
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.